Pharmaceutical Business News

Set Back for Pancreatic Cancer: CARRIE study did not meet primary or secondary endpoints

Merrimack Pharmaceuticals, Inc., a clinical-stage oncology company focused on biomarker-defined cancers, today announced top-line results from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141 (istiratumab) to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer and high serum levels of free Insulin-like Growth Factor-1 (IGF-1). The study did not […]

Pharmaceutical Business News

FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). “This is the first treatment approved for stage III […]

Cancer Discovery

Is anti-angiogenic therapy to treat glioblastomas a viable option?

Results of two phase 2 clinical trials testing cabozantinib suggest that anti-angiogenic therapy could be used to treat glioblastomas Glioblastoma is an aggressive type of brain tumor that affects approximately 74,000 individuals across the world, annually. The current standard of treatment for this tumour type consists of surgical removal of the tumor, accompanied with radiation […]

cancer Cancer Discovery

Early Evidence of Efficacy and Safety Seen in Novel Targeted Immunotherapy

An immune-oncology focused biotechnology company, BriaCell, has provided a clinical update on its lead immunotherapy drug for advanced breast cancer. BriaCell provided further update on its ongoing clinical trial of Bria-IMT™ according to Protocol WRI-GEV-007 (listed in ClinicalTrials.gov as NCT03066947).  Six patients have received inoculations since the trial began in early 2017, with the observation […]

Biotechnology cancer Gene Therapy Immunotherapies

Liver Cancer Patients Can Start with Lower Dose of Chemotherapy and Live Just as Long

Penn study shows patients can benefit from fewer side effects and lower treatment costs Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not affect how long they live when compared to […]

ASCO 2017 cancer

Long Term Survival Indicated for Advanced Stage Colorectal Cancer Patients who Survive at Least Two Years

Improvements in chemotherapy and liver surgery have resulted in increased overall survival in patients with advanced stage colorectal cancer in recent decades. In order to better predict outcomes for these patients, researchers at Rutgers Cancer Institute of New Jersey conducted a retrospective analysis and found that stage IV colorectal cancer patients who survived at least […]

Biotechnology cancer Clinical Trials Immunotherapies

New Ovarian Cancer Immunotherapy Study Poses Question: Can Microbiome Influence Treatment Response?

Roswell Park Study with pembrolizumab in untried combination is first ovarian cancer clinical trial to incorporate gut flora analysis A new clinical study underway at Roswell Park Cancer Institute is the first to test the combination of the immunotherapy pembrolizumab with two other drugs as treatment for recurrent epithelial ovarian cancer, and is also the […]

cancer Neurology

Medulloblastoma Patients Should Receive Both Chemotherapy And Radiation Post-Surgery

In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival. The benefit of chemotherapy, in addition to craniospinal radiation, was seen in adult patients with medulloblastoma (MB), including those with localized disease who received high-dose radiation treatment following surgery. The findings […]